These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 33623809)

  • 1. Characteristics of the First 102 Severe COVID-19 Cases Treated With Convalescent Plasma or Tocilizumab or Both in Al-Nahdha Hospital, Oman.
    Al Harthi S; Osali MA; Kindi NA; Kharusi ZA; Qasabi SA; Hinai MA; Ghafri TA
    Health Serv Res Manag Epidemiol; 2021; 8():2333392820986639. PubMed ID: 33623809
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical Characteristics of Confirmed Cases of COVID-19 Admitted at Al Nahdha Hospital, Oman: A Cross-Sectional Descriptive Study.
    Al Harthi S; Al Osali M; Al Ismaili R; Al Lawati S; Kamble B; Al Shaaibi M; Al Kindi N; Al Qasabi S; Alhinai M; Al Harthi H; Al Ghafri TS
    Cureus; 2021 Aug; 13(8):e17343. PubMed ID: 34567884
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
    Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
    Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tocilizumab in SARS-CoV-2 Patients with the Syndrome of Cytokine Storm: A Narrative Review.
    Kulanthaivel S; Kaliberdenko VB; Balasundaram K; Shterenshis MV; Scarpellini E; Abenavoli L
    Rev Recent Clin Trials; 2021; 16(2):138-145. PubMed ID: 32940187
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tocilizumab Treatment for Cytokine Release Syndrome in Hospitalized Patients With Coronavirus Disease 2019: Survival and Clinical Outcomes.
    Price CC; Altice FL; Shyr Y; Koff A; Pischel L; Goshua G; Azar MM; Mcmanus D; Chen SC; Gleeson SE; Britto CJ; Azmy V; Kaman K; Gaston DC; Davis M; Burrello T; Harris Z; Villanueva MS; Aoun-Barakat L; Kang I; Seropian S; Chupp G; Bucala R; Kaminski N; Lee AI; LoRusso PM; Topal JE; Dela Cruz C; Malinis M
    Chest; 2020 Oct; 158(4):1397-1408. PubMed ID: 32553536
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical efficacy of tocilizumab treatment in severe and critical COVID-19 patients.
    Zeng J; Xie MH; Yang J; Chao SW; Xu EL
    World J Clin Cases; 2020 Sep; 8(17):3763-3773. PubMed ID: 32953852
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of severely ill COVID-19 patients with anti-interleukin drugs (COV-AID): A structured summary of a study protocol for a randomised controlled trial.
    Maes B; Bosteels C; De Leeuw E; Declercq J; Van Damme K; Delporte A; Demeyere B; Vermeersch S; Vuylsteke M; Willaert J; Bollé L; Vanbiervliet Y; Decuypere J; Libeer F; Vandecasteele S; Peene I; Lambrecht B
    Trials; 2020 Jun; 21(1):468. PubMed ID: 32493441
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of dexamethasone and tocilizumab on hematological parameters in COVID-19 patients with chronic disease.
    Qutob HMH; Saad RA; Bali H; Osailan A; Jaber J; Alzahrani E; Alyami J; Elsayed H; Alserihi R; Shaikhomar OA
    Med Clin (Engl Ed); 2022 Dec; 159(12):569-574. PubMed ID: 36536624
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tocilizumab Use in COVID-19 Cytokine-release Syndrome: Retrospective Study of Two Centers.
    Nasa P; Singh A; Upadhyay S; Bagadia S; Polumuru S; Shrivastava PK; Sankar R; Vijayan L; Soliman MA; Ali A; Patidar S
    Indian J Crit Care Med; 2020 Sep; 24(9):771-776. PubMed ID: 33132558
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tocilizumab for treatment of mechanically ventilated patients with COVID-19.
    Somers EC; Eschenauer GA; Troost JP; Golob JL; Gandhi TN; Wang L; Zhou N; Petty LA; Baang JH; Dillman NO; Frame D; Gregg KS; Kaul DR; Nagel J; Patel TS; Zhou S; Lauring AS; Hanauer DA; Martin E; Sharma P; Fung CM; Pogue JM
    medRxiv; 2020 Jun; ():. PubMed ID: 32577684
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Secondary Infections in Patients with COVID-19 Pneumonia Treated with Tocilizumab Compared to Those Not Treated with Tocilizumab: A Retrospective Study at a Tertiary Hospital in Kenya.
    Shah R; Shah J; Gohil J; Revathi G; Surani S
    Int J Gen Med; 2022; 15():2415-2425. PubMed ID: 35264878
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A prospective, randomised, double blind placebo-controlled trial to evaluate the efficacy and safety of tocilizumab in patients with severe COVID-19 pneumonia (TOC-COVID): A structured summary of a study protocol for a randomised controlled trial.
    Rilinger J; Kern WV; Duerschmied D; Supady A; Bode C; Staudacher DL; Wengenmayer T
    Trials; 2020 Jun; 21(1):470. PubMed ID: 32493514
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tocilizumab as a Treatment for 'Cytokine Storm Syndrome' in COVID-19: A Case Report.
    Syam AF; Pitoyo CW; Suhendro S; Zulkarnain B; Indrasari ND; Aditianingsih D; Irawan C; Susilo A; Rumende CM; Wijaya IP; Ibrahim F; Rasmin M; Alwi I; Makmun D
    Acta Med Indones; 2021 Apr; 53(2):194-201. PubMed ID: 34251348
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative Survival Analysis of Immunomodulatory Therapy for Coronavirus Disease 2019 Cytokine Storm.
    Narain S; Stefanov DG; Chau AS; Weber AG; Marder G; Kaplan B; Malhotra P; Bloom O; Liu A; Lesser ML; Hajizadeh N;
    Chest; 2021 Mar; 159(3):933-948. PubMed ID: 33075378
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of tocilizumab administration on mortality in severe COVID-19.
    Tsai A; Diawara O; Nahass RG; Brunetti L
    Sci Rep; 2020 Nov; 10(1):19131. PubMed ID: 33154452
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Double-blind, randomized, controlled, trial to assess the efficacy of allogenic mesenchymal stromal cells in patients with acute respiratory distress syndrome due to COVID-19 (COVID-AT): A structured summary of a study protocol for a randomised controlled trial.
    Payares-Herrera C; Martínez-Muñoz ME; Vallhonrat IL; de Molina RM; Torres MP; Trisan A; de Diego IS; Alonso R; Zafra R; Donaire T; Sánchez R; Rubio JJ; Duarte Palomino RF; Solá CA
    Trials; 2021 Jan; 22(1):9. PubMed ID: 33407777
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Early identification of COVID-19 cytokine storm and treatment with anakinra or tocilizumab.
    Langer-Gould A; Smith JB; Gonzales EG; Castillo RD; Figueroa JG; Ramanathan A; Li BH; Gould MK
    Int J Infect Dis; 2020 Oct; 99():291-297. PubMed ID: 32768693
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical experience of tocilizumab treatment among a cohort of patients with COVID-19 infection from Western India.
    Surana PD; Nayak R; Sheikh A; Haldankar P; Kale J
    J Family Med Prim Care; 2022 Jan; 11(1):123-132. PubMed ID: 35309657
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of dexamethasone and tocilizumab on hematological parameters in COVID-19 patients with chronic disease.
    Qutob HMH; Saad RA; Bali H; Osailan A; Jaber J; Alzahrani E; Alyami J; Elsayed H; Alserihi R; Shaikhomar OA
    Med Clin (Barc); 2022 Dec; 159(12):569-574. PubMed ID: 35659421
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A prospective, randomized, controlled study assessing vagus nerve stimulation using the gammaCore®-Sapphire device for patients with moderate to severe CoViD-19 Respiratory Symptoms (SAVIOR): A structured summary of a study protocol for a randomised controlled trial".
    Tornero C; Vallejo R; Cedeño D; Orduña J; Pastor E; Belaouchi M; Escamilla B; Laredo M; Del Mar Garzando M
    Trials; 2020 Jun; 21(1):576. PubMed ID: 32586395
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.